<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02697136</url>
  </required_header>
  <id_info>
    <org_study_id>CER-001-CLIN-009</org_study_id>
    <nct_id>NCT02697136</nct_id>
  </id_info>
  <brief_title>CER-001 Therapy as a Novel Approach to Treat Genetic Orphan Diseases</brief_title>
  <acronym>TANGO</acronym>
  <official_title>Phase 3, Multicenter, Randomized, 48 Week, Double Blind, Parallel Group, Placebo Controlled Study to Evaluate Efficacy and Safety of CER-001 on Vessel Wall Area in Patients With Genetically Defined Familial Primary Hypoalphalipoproteinemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cerenis Therapeutics, SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cerenis Therapeutics, SA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the impact of 29 intravenous infusions of CER-001 vs.
      placebo, given at weekly (9 infusions) and biweekly (20 infusions) intervals on carotid
      vessel wall area as measured by 3TMRI, when administered to patients with familial primary
      hypoalphalipoproteinemia with proven CVD and appropriate background lipid-lowering therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will be required to have acceptable baseline 3TMRI imaging of carotid arteries.
      Subjects meeting all eligibility criteria will be randomized to receive CER-001 or placebo
      (2:1 randomization scheme). Randomized subjects will return weekly for a total of 9 infusions
      and then biweekly for an additional 20 infusions. 3TMRI imaging of the carotid and femoral
      arteries will be performed at Week 8, Week 24 (primary endpoint) and Week 48. The total study
      duration from randomization can range from 50 to 54 weeks for patients completing the study
      as designed.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in mmean vessel wall area (MVWA) of the carotid artery</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>Change from baseline to Week 24 carotid MVWA; CER-001 versus placebo; measured by 3TMRI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in mean vessel wall area (MVWA) of the carotid artery</measure>
    <time_frame>Baseline to Week 8</time_frame>
    <description>Change from baseline to Week 8 carotid MVWA; CER-001 versus placebo; measured by 3TMRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mean vessel wall area (MVWA) of the carotid artery</measure>
    <time_frame>Baseline to Week 48</time_frame>
    <description>Change from baseline to Week 48 carotid MVWA; CER-001 versus placebo; measured by 3TMRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Target to Background Ratio (TBR) of the carotid artery</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>Change from baseline to Week 24 in carotid TBR; CER-001 versus placebo; measured by FDG-PET</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in femoral MVWA</measure>
    <time_frame>Baseline, Weeks 8, 24 and 48</time_frame>
    <description>Assessed by 3TMRI; change from baseline; CER-001 versus placebo</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Familial Hypoalphalipoproteinemia</condition>
  <arm_group>
    <arm_group_label>CER-001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CER-001 infusion; 9 weekly infusions followed by 20 biweekly infusions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline infusion; 9 weekly infusions followed by 20 biweekly infusions</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CER-001</intervention_name>
    <description>Recombinant human apoA-I/phospholipid complexes</description>
    <arm_group_label>CER-001</arm_group_label>
    <other_name>CAS 138-3435-67-3</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0.9% Sodium Chloride Injection, USP</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Normal saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:

          -  Male and female patients, aged 18 and above.

          -  ApoA-I &lt; 70 mg/dL

          -  Symptomatic or asymptomatic cardiovascular disease

          -  Diagnosis of genetically confirmed HDL-c deficiency due to defects in genes coding for
             ABCA1 and/or ApoA-1

          -  Stable doses of lipid lowering therapies for at least 6 weeks prior to baseline
             procedures

        Main Exclusion Criteria:

          -  Females of childbearing potential

          -  Patients with LCAT mutations

          -  Patients who experienced recent cardiovascular or cerebrovascular events

          -  Hypertriglyceridemia (&gt;500 mg/dL)

          -  Severe anemia (Hgb &lt; 10 g/dL)

          -  Uncontrolled diabetes (HbA1c &gt;10%)

          -  Congestive heart failure (NYHA class II or higher)

          -  Contraindication for MRI scanning (e.g., implanted metal objects, claustrophobia)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Erik SG Stroes, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Connie Keyserling, MS</last_name>
    <phone>+33 5 6224 0520</phone>
    <email>keyserling@cerenis.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>La Louvi√®re</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Chicoutimi</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Jerusalem Region</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Genoa</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 17, 2016</study_first_submitted>
  <study_first_submitted_qc>February 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2016</study_first_posted>
  <last_update_submitted>March 16, 2017</last_update_submitted>
  <last_update_submitted_qc>March 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Low HDL</keyword>
  <keyword>Low apoA-I</keyword>
  <keyword>ABCA-1 mutations</keyword>
  <keyword>ApoA-I mutations</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypoalphalipoproteinemias</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>To be determined</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

